IGM-2320

N/A

Report date: 2022/07/01 15:29:28

NME

Base Information

Drug NameIGM-2320

Drug Alias NameIGM-2320

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIgm Biosciences Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsLeukemia, B-Cell

Inactive IndicationsN/A

ATC CodeN/A